Day 1 - Wednesday, 14 June 2017
Meeting category
Date(s)
14 Jun 2017 - 16 Jun 2017
Location
Chicago,
United States
Organizer
Titanium Level Support
Sponsor logos
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2017
Related Enduring Materials
Enduring Materials
Session 2: The Complexity of DDIs Involving PK Enhancement -
O_2: Effects of cobicistat on tenofovir durability: is it time to rethink at TAF trials?
O_3: Pharmacokinetics of darunavir/cobicistat and etravirine alone and coadministered in HIV-infected patients
O_4: Evaluation of the Drug-Drug Interaction Potential between Cobicistat-Boosted Protease Inhibitors and Statins
O_5: Confirmation of the drug-drug interaction (DDI) potential between cobicistat-boosted antiretroviral regimens and hormonal contraceptives
O_6: Darunavir concentrations in CSF of HIV-infected individuals when boosted with cobicistat versus ritonavir
Day 2 - Thursday, 15 May 2017
Session 3: Challenges and Approaches to Treatment in Special Patient Populations -
O_7: A Comparison of the Pharmacokinetics of Dolutegravir during Pregnancy and Postpartum
O_8: Relationship between dolutegravir plasma exposure, quality of sleep and its functional outcome in patients living with HIV over the age of 60 years.
Session 4: Hepatitis B Virus -
HBV therapy & Approaches to Cure
Session 5: Exploration of Less-drug Regimens -
O_10: Pharmacokinetics of Dolutegravir and Rilpivirine after Switching to the Two-Drug Regimen from an Efavirenz- or Nevirapine-Based Antiretroviral Regimen: SWORD-1/2 Pooled PK Analysis
O_11: HIV-1-infected Males and Females under Less-Drug Regimens Achieve Antiretroviral Levels above the Inhibitory Concentration in the Genital Tract.
Session 6: Implications of Drug Transport and Metabolism in Drug Development -
Transporter mediated DDI
Kathy Giacomini, PhD
University of California, San Francisco, USA
O_12: Examining the Basis of Drug-Drug Interaction Labeling Recommendations for Antiviral Approvals from 1998 to 2015
O_13: CYP3A induction data can predict other P450 and drug transporter DDI liability: An example of carbamazepine and rifabutin with sofosbuvir and P-gp
Session 7: Clinical Cases Discussions -
Challenges in managing the aging HIV-infected patient
Babafemi Taiwo, MBBS
Northwestern University, USA
DDI’s in Aging HIV infected Patients
Day 3 - Friday, 16 June 2017
Session 8: Long Acting Antivirals: Advanced drug delivery -
O_14: Pharmacokinetics of Co-encapsulated Truvada® with Ingestible Sensor to Assess Adherence
O_15: Identification of long-acting NRTI candidates through in silico modelling
O_16: A mathematical model that predicts virological failure and elucidates the impact of lymph node drug penetration
O_17: Early Safety, Tolerability, and Pharmacokinetic Profile of GSK2838232, a Novel 2nd Generation HIV Maturation Inhibitor, as Assessed in Healthy Subjects
Session 9: Hepatitis C Virus -
O_18: Drug-drug interactions of Glecaprevir and Pibrentasvir with Pravastatin, Rosuvastatin, or Dabigatran etexilater
O_19: Influences on Pharmacokinetics of ledipasvir, sofosbuvir and GS-331007 in patients with decompensated cirrhosis – results from the UK Expanded Access programme
O_20: Evaluation of Drug-Drug Interactions between Sofosbuvir/Velpatasvir/Voxilaprevir and Boosted or Unboosted HIV Antiretroviral Regimens
O_21: The Potential Role of PK-Based Drug Interactions in FAERS-Reported Rhabdomyolysis Cases in Patients Receiving a DAA Regimen and a Statin
Su-Young Choi, PharmD, PhD
Clinical Pharmacology Reviewer Office of Clinical Pharmacology CDER/FDA
Debate: Do we need more HCV Drugs?
Con Standpoint
Overview
Overview
Dear Colleague,
We are very pleased with a very successful edition of the International Workshop on Clinical Pharmacology of Antiviral Therapy (formally known as the International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy), which has taken place 14 - 16 June 2017 in Chicago, IL, USA.
The 18th edition of the meeting has provided a platform for state-of-the-art discussions of current topics fundamental to the optimal use of antiretroviral therapy. Experts have delivered exceptional talks on a variety of topics and young and established researchers have presented their latest reseach results during oral abstract presentations and poster viewing sessions.
We would also like to dedicate our gratitude to our sponsors, ViiV Healthcare, Gilead, Abbvie, Janssen and Mylan, for their generous support that made this event possible.
On behalf of the entire Organizing Committee.
The workshop chairs,
Chairs
Committees
The Workshop Chairs
Support
Language
Related Programs
